Veracyte Future Growth

Future criteria checks 1/6

Veracyte is forecast to grow earnings and revenue by 115.2% and 10.1% per annum respectively. EPS is expected to grow by 116.8% per annum. Return on equity is forecast to be 0.3% in 3 years.

Key information

115.2%

Earnings growth rate

116.8%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate10.1%
Future return on equity0.3%
Analyst coverage

Good

Last updated26 Feb 2024

Recent future growth updates

Recent updates

Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

Apr 18
Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S

A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Mar 18
A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)

Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk

Jul 13

Veracyte: Not A Healthy Diagnosis

May 12

Valuing Veracyte Stock

Oct 03

Earnings and Revenue Growth Forecasts

NasdaqGM:VCYT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026491-132N/A4
12/31/2025443-418N/A9
12/31/2024398-1815N/A9
12/31/2023361-743444N/A
9/30/2023343-502938N/A
6/30/2023329-292331N/A
3/31/2023311-30714N/A
12/31/2022297-37-18N/A
9/30/2022284-43-16N/A
6/30/2022268-49-10-2N/A
3/31/2022251-48-70N/A
12/31/2021220-76-37-32N/A
9/30/2021187-73-43-38N/A
6/30/2021157-63-39-35N/A
3/31/2021123-65-48-45N/A
12/31/2020117-35-13-10N/A
9/30/2020113-34-13-10N/A
6/30/2020113-31-16-13N/A
3/31/2020122-22-10-8N/A
12/31/2019120-13-6-3N/A
9/30/2019116-8-8-6N/A
6/30/2019109-12-9-6N/A
3/31/2019101-16-10-7N/A
12/31/201892-23-15-14N/A
9/30/201886-28-20-18N/A
6/30/201880-31-23-21N/A
3/31/201876-32-25-23N/A
12/31/201772-31-26-24N/A
9/30/201771-27N/A-22N/A
6/30/201772-26N/A-25N/A
3/31/201768-29N/A-27N/A
12/31/201665-31N/A-28N/A
9/30/201661-35N/A-27N/A
6/30/201655-38N/A-23N/A
3/31/201652-36N/A-27N/A
12/31/201550-34N/A-27N/A
9/30/201548-34N/A-33N/A
6/30/201545-33N/A-35N/A
3/31/201542-30N/A-30N/A
12/31/201438-29N/A-28N/A
9/30/201433-27N/A-22N/A
6/30/201429-26N/A-21N/A
3/31/201425-25N/A-19N/A
12/31/201322-26N/A-19N/A
9/30/201320-25N/A-20N/A
6/30/201317-23N/A-20N/A
3/31/201315-21N/A-20N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VCYT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VCYT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VCYT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VCYT's revenue (10.1% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: VCYT's revenue (10.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VCYT's Return on Equity is forecast to be low in 3 years time (0.3%).


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.